Deliverx Pharma宣布针对Quumulus AI组合的不具约束力的RTI

2025-03-18 22:03

Vincerx Pharma (NASDAQ:VINC) has entered into a non-binding LOI with Global Digital Holdings, conducting business as QumulusAI, relating to a business combination between Vincerx and QumulusAI.
The contemplated transaction would result in QumulusAI becoming a publicly traded company through a reverse triangular merger with Vincerx.
Under the proposed terms, a subsidiary of Vincerx would merge into QumulusAI, with QumulusAI stockholders receiving shares of Vincerx common stock.
The exchange ratio is intended to result in QumulusAI equity holders owning ~95% of the combined company, while Vincerx equity holders would own ~5%.
The proposed transaction assumes a value for QumulusAI of ~$285M and a value for Vincerx of ~$15M, assuming zero cash at closing.
“We believe this merger will allow us to create value for our stockholders by entering the AI space at a time of rapid growth,” said Raquel Izumi, Ph.D., Acting Chief Executive Officer of Vincerx.
VINC +20.6% to $1.00.

More on Vincerx Pharma